NKB

Research news on Parkinson’s - Norwegian Center for Movement Disorders / Nyheter og forskning om PS - Nasjonal kompetansetjeneste for bevegelsesforstyrrelser

[NKB @ParkinsonNKB]

🌟Exceptional reviews for ParkinsonNet Norway at @arendalsuka! 🌟 The future for providing care in #Parkinsons looks promising with our model 🚀 Read more in @DagensMedisin #ParkinsonNetNorway #Arendalsuka #Healthcare

https://t.co/DIOD2DRi2P

[NKB @ParkinsonNKB]

We had a fantastic time meeting the PICC cohort in person. There are some truly exciting projects emerging from this incredible group 🙌

https://t.co/tLkvZbpR7C

[Jodi Grødem @JoGrodem]

It was incredible to be part of the group of volunteers at #WPC2023

[NKB @ParkinsonNKB]

We hope you got to catch some of the work at @ParkinsonNKB were presenting this week. It’s been great to meet so many people @WorldPDCongress !

[NKB @ParkinsonNKB]

It was a great day at *Lewy Body UK* to discuss all the advances that are being made in #LewyBodyDementia

[DEBRA UK @CharityDEBRA]

21 miles, completed it! ✅

A huge thank you to Graeme, Andy, Sean, Steph, Rob and Andy M for taking on this challenge to help #StopThePain for people living with EB.

Donate today and help us find treatments for this cruel condition: https://t.co/PULH0KGBo0 🦋

#GraemeSouness

[NKB @ParkinsonNKB]

Neuroinflammation contributes to #neurodegeneration 🧠Here we explored the value of inflammation-related biomarkers in Parkinson’s Disease, dementia with Lewy bodies, and Alzheimer’s disease, and identified disease-specific biomarker panels
https://t.co/Nkbe6PIJsO

[NKB @ParkinsonNKB]

Debate persists: are DLB & PDD distinct phenotypes? 🧠 In a study by @mc_gonzalez_MD in @MDCP_Journal, we showed that DLB and PDD patients experienced similar rates of cognitive and motor decline. This is relevant for future clinical trial designs.
https://t.co/hxhvWPKAzD

[NKB @ParkinsonNKB]

That’s a wrap for #ADPD2023 ! What an amazing congress with so many great people. See you all in Lisbon for #ADPD2024 when we’ll try to remember to take a lab photo with everyone! Congrats to @mc_gonzalez_MD and @JoGrodem for staying until the very end!

[NKB @ParkinsonNKB]

Great to see @JoGrodem presenting on behalf of @ParkinsonNKB on the last day of #ADPD2023

[Maria Camila Gonzalez @mc_gonzalez_MD]

Feeling really inspired after my supervisor Dr. Jodi Maple-Grødem's presentation on GCASE activity and the LONG-TERM RISK of cognitive decline in PD. #adpd23 @ParkinsonNKB

[Maria Camila Gonzalez @mc_gonzalez_MD]

Officially in the contest 📸@carlaabdelnour #ADPD2023 @adpdnet

[NKB @ParkinsonNKB]

Join us for the last session today at #ADPD2023 to hear about @ParkinsonNKB‘s work on GCase activity in #Parkinsons

[NKB @ParkinsonNKB]

If you’re one of the 4000 people lucky enough to be at #ADPD2023, please come and talk to us today about some of our newest biomarker work, presented by Johannes Lange (#657) and @mc_gonzalez_MD (#348)

[NKB @ParkinsonNKB]

Congratulations to Christina Pedersen who gave a great talk about her work on the development of sensitive biomarkers in Parkinson @UniStavanger

[Cure Parkinson's @CureParkinsonsT]

(1/2) Breaking news: A large phase 3 trial of ambroxol currently used to treat cough inflammation is to start in early 2023. This world-first trial will aim to establish its potential to slow the progression of Parkinson’s.

https://t.co/5iPmn03UxN

@VAInstitute @ParkinsonsUK

[NeurologyLive® @neurology_live]

A population-based longitudinal study showed that reduced cerebrospinal fluid lysosomal enzyme glucocerebrosidase activity at the time of #PD diagnosis is associated with an increased risk for PD #dementia. @GreenJournal

Read 📗: https://t.co/zCxUVIZ5DU

[NKB @ParkinsonNKB]

It was wonderful to welcome Dr Hayley MacDonald from the University of Bergen today and hear about her work on behavioural, neurophysiological and genetic mechanisms of impulse control #Parkinson

[NKB @ParkinsonNKB]

It is great to be back in person for the annual ParkWest meeting, bringing together some of the people who make the Norwegian ParkWest study possible and hearing about the exciting work coming from this diverse team! #Parkinsons

[The Science of Parkinson's @ScienceofPD]

Interesting: GCase activity at time of diagnosis was lower in #Parkinsons patients who developed dementia within 10 years than in those who did not (p = 0.001). A 0.1 unit reduction in baseline GCase activity was associated with a faster development of PDD
https://t.co/0LxV5iEksf

[NKB @ParkinsonNKB]

Congratulations to our team at @ParkinsonNKB on the publication of exciting work showing that CSF GCase activity at PD diagnosis is linked to the future risk of dementia. These results could have important implications for #clinicaltrials in #parkinsons https://t.co/F6ou20uaj2